论文部分内容阅读
目的:探讨恶性肿瘤外周血CD4+CD25+调节T细胞水平的特点及其临床意义。方法:采用流式细胞术检测53例恶性肿瘤患者外周血CD4+CD25+调节T细胞水平及淋巴细胞亚群,并进行分层分析。结果:外周血淋巴细胞亚群分析显示:恶性肿瘤患者CD4、CD16阳性细胞比例在早期(Ⅰ+Ⅱ期)患者即低于对照组,但差异无显著性意义(P>0.05),CD4CD8亦低于对照组,差异有显著性意义(P<0.05);随着疾病进展(Ⅲ、Ⅳ期)CD4、CD4/CD8、CD16阳性细胞比例减低明显,差异有显著性意义(P<0.05);各期CD8、CD19、CD3与对照组接近(P>0.05)。外周血CD4+CD25+调节T细胞比例:健康对照组CD4+CD25+T细胞水平为(14.49±4.69)%,恶性肿瘤53例CD4+CD25+T细胞比例为(19.61±8.17)%,统计学有差异(P<0.05);进一步分层分析显示:随疾病进展外周血CD4+CD25+T细胞水平升高,在肿瘤进展期(Ⅳ期)尤其明显,统计学有极显著差异(P<0.01)。结论:恶性肿瘤患者外周血CD4+CD25+调节T细胞水平的升高,与恶性肿瘤免疫功能低下及肿瘤的发生发展密切相关。去除这群细胞可有效诱导肿瘤免疫,为肿瘤治疗提供一种新的方法。
Objective: To investigate the characteristics and clinical significance of CD4 + CD25 + regulatory T cells in peripheral blood of malignant tumors. Methods: The levels of CD4 + CD25 + regulatory T cells and lymphocyte subsets in peripheral blood of 53 patients with malignant tumor were detected by flow cytometry and stratified analysis. Results: The analysis of peripheral blood lymphocyte subsets showed that the proportion of CD4 and CD16 positive cells in patients with malignant tumors was lower in the early stage (stage Ⅰ + Ⅱ) than in the control group, but the difference was not statistically significant (P0.05) (P <0.05). The proportion of CD4, CD4 / CD8 and CD16 positive cells decreased significantly with the progression of disease (stage Ⅲ and Ⅳ) (P <0.05), and the difference was statistically significant Stage CD8, CD19, CD3 and control group close (P> 0.05). The proportion of CD4 + CD25 + regulatory T cells in peripheral blood was (14.49 ± 4.69)% in healthy controls and (19.61 ± 8.17)% in 53 cases of malignant tumors (P <0.05). Further stratification analysis showed that CD4 (superscript +) CD25 (superscript +) T cells increased with the progress of disease, especially in stage Ⅳ (P <0.01) . Conclusion: The increase of CD4 + CD25 + regulatory T cells in peripheral blood of patients with malignant tumor is closely related to the immunodeficiency of malignant tumor and the occurrence and development of tumor. Removal of these cells can effectively induce tumor immunity, providing a new method for cancer treatment.